ID   HCC4006-OsiR
AC   CVCL_A7EW
DR   cancercelllines; CVCL_A7EW
DR   Wikidata; Q107115246
RX   PubMed=32928921;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:90943; Osimertinib (AZD9291).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1269 ! HCC4006
SX   Male
AG   >50Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 05-10-23; Version: 6
//
RX   PubMed=32928921; DOI=10.1158/0008-5472.CAN-20-1634;
RA   Sun Y.-T., Meyers B.A., Czako B., Leonard P., Mseeh F., Harris A.L.,
RA   Wu Q., Johnson S., Parker C.A., Cross J.B., Di Francesco M.E.,
RA   Bivona B.J., Bristow C.A., Burke J.P., Carrillo C.C., Carroll C.L.,
RA   Chang Q., Feng N.-P., Gao G., Gera S., Giuliani V., Huang J.K.,
RA   Jiang Y.-Y., Kang Z.-J., Kovacs J.J., Liu C.-Y., Lopez A.M., Ma X.-Y.,
RA   Mandal P.K., McAfoos T., Miller M.A., Mullinax R.A., Peoples M.,
RA   Ramamoorthy V., Seth S., Spencer N.D., Suzuki E., Williams C.C.,
RA   Yu S.S., Zuniga A.M., Draetta G.F., Marszalek J.R., Heffernan T.P.,
RA   Kohl N.E., Jones P.;
RT   "Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and
RT   EGFR-independent resistance mechanisms toward osimertinib.";
RL   Cancer Res. 80:4840-4853(2020).
//